<DOC>
	<DOCNO>NCT01587365</DOCNO>
	<brief_summary>To obtain safety tolerability information healthy subject administer single dose</brief_summary>
	<brief_title>Single Ascending Dose Safety Study BMS-962476 Healthy Subjects Patients With Elevated Cholesterol Statins</brief_title>
	<detailed_description>- Study Classification : Pharmacokinetics Pharmacodynamics - Intervention Model : Single Ascending Dose ( SAD ) study - Allocation : Randomized Non-Stratified</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Healthy population Untreated low density lipoprotein cholesterol ( LDLc ) ≥ 130 ≤ 190 mg/dL triglyceride ≤ 200 mg/dL Body Mass Index ( BMI ) 18 35 kg/m2 inclusive Men woman , age 18 65 year , inclusive Statin population Patients hypercholesterolemia stable statin therapy 6 week prior enrollment At enrollment , LDLc ≥ 100mg/dL triglyceride ≤ 200 mg/dL Patients control hypertension stable dose two antihypertensive drug BMI 18 37 kg/m2 inclusive Men woman , age 18 75 year inclusive Healthy Population Subjects fast LDLc &lt; 130 &gt; 190 mg/dL , fast triglyceride &gt; 200 mg/dL Subjects increase 10year cardiovascular risk ≥ 20 % base Framingham risk score Subjects significant acute chronic medical illness time screening , include history cancer , know history sickle cell disease trait , know history thalassemia Statin population Patients fast LDLc &lt; 100mg/dL , fast triglyceride &gt; 200 mg/dL statin therapy Patients prescription counter lipidlowering therapy statin therapy Patients establish atherosclerotic vascular disease Patients diabetes require oral injectable antidiabetic drug therapy Patients uncontrolled hypertension control hypertension require two antihypertensive drug Patients significant acute chronic medical illness severe , progressive uncontrolled time screen Use lipid lower medication include counter product ( eg , niacin &gt; 500 mg ; omega3 fatty acid &gt; 1000 mg ; red rice yeast ; phytosterols stanol ester ) lipid lower within 30 day prior screen visit ( 42 day fibrates ) exception stable statin therapy target disease population Prior treatment monoclonal antibody investigational protein biologic within precede one year study drug administration Concurrent use within 3 month study drug administration market investigational systemic inhale corticosteroid immunosuppressant drug , within 6 week topical corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>